by Jen Peters | Jun 22, 2022 | Home News (Left), News, News-2022
News & Events News TriSalus Life Sciences Provides Update on Development of Immunotherapy Platform Approach for Liver and Pancreatic Tumors DENVER and CHICAGO, JUNE 22, 2022 – TriSalus Life Sciences®, an immunotherapy company on a mission to extend and improve the...
by Jen Peters | Jun 6, 2022 | Home News (Left), News, News-2022
News & Events News TriSalus Life Sciences to Present at the Society of Interventional Radiology’s 2022 Annual Scientific Meeting *** MEDIA ADVISORY *** BOSTON, June 6, 2022 – TriSalus Life Sciences®, an interventional immunotherapy company on a mission to extend and...
by Jen Peters | Jun 3, 2022 | Events, Home News (Left)
News & Events News TriSalus Life Sciences to Present at the Society of Interventional Radiology’s 2022 Annual Scientific Meeting *** MEDIA ADVISORY *** BOSTON, June 6, 2022 – TriSalus Life Sciences®, an interventional immunotherapy company on a mission to extend and...
by Jen Peters | Sep 7, 2021 | Home News (Left), News, News-2021
News & Events News TriSalus Life Sciences Announces First Patient Enrolled in PERIO-01 Clinical Trial to Evaluate Delivery of SD-101 via Pressure-Enabled Drug Delivery in Uveal Melanoma Liver Metastases Study to evaluate the delivery of SD-101, an investigational TLR9...
by Jen Peters | Apr 14, 2021 | Home News (Left), News, News-2021
News & Events News TriSalus Life Sciences Presents Data at American Association of Cancer Research Showing Reduced Liver Tumor Burden from Toll-Receptor Agonists Regional Delivery of Oligodeoxynucleotides (ODN2395) Showed Activation of Toll-Like Receptor Agonist in...
Recent Comments